Medicare AdvantageCoverageMedium impact
MA08.009w, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Independence Blue Cross·Allergy & Immunology, Neurology, Hematology +3 more·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.009w for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) has been updated effective January 1, 2025. This policy change affects coverage criteria and billing requirements for immunoglobulin therapy administration.
Action Required
Immediately: Billing team must review updated MA08.009w policy for IVIG/SCIG coverage criteria and billing requirements. Update prior authorization protocols and documentation requirements for Medicare Advantage patients receiving immunoglobulin therapy. Verify current billing practices align with new policy guidelines to prevent claim denials.